Fiche centre
Arkansas Children's Hospital
Little Rock — United States
Essais liés22clinical trials
VilleLittle Rocklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06138639
Essais cliniques associés
22| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Biopsy Procedure | Cancer | Phase 1/2 | NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | RECRUITING |
| Biopsy Procedure | Cancer | Phase 2 | NCT06064097 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT05066217 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | RECRUITING |
| Duchenne Electronic Health Record Study | Myopathies | À vérifier | NCT07609394 | Duchenne Electronic Health Record Study | RECRUITING |
| Deramiocel (CAP-1002) | Myopathies | Phase 3 | NCT05126758 | HOPE-3 — A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Bone Scan | Cancer | Phase 2/3 | NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | SUSPENDED |
| PBGENE-DMD (IV) | Myopathies | Phase 1/2 | NCT07429240 | PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) | RECRUITING |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT07678775 | Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | ACTIVE_NOT_RECRUITING |
| SGT-003 | Myopathies | Phase 1/2 | NCT06138639 | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | RECRUITING |
| RGX-202 | Myopathies | Phase 2/3 | NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| PF-06939926 | Myopathies | Phase 3 | NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| CDLink — CureDuchenne Link®: A Resource for Research | Myopathies | À vérifier | NCT04972604 | CDLink — CureDuchenne Link®: A Resource for Research | COMPLETED |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | ACTIVE_NOT_RECRUITING |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension | Myopathies | À vérifier | NCT06747884 | TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension | RECRUITING |
| delpacibart zotadirsen | Myopathies | À vérifier | NCT07250737 | Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping | AVAILABLE |
| SGT-003 | Myopathies | Phase 3 | NCT07160634 | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) | RECRUITING |
| Satralizumab | Myopathies | Phase 2 | NCT06450639 | SHIELD DMD — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |